161 related articles for article (PubMed ID: 38558740)
41. A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt.
Elezbawy B; Fasseeh AN; Sedrak A; Eldessouki R; Gamal M; Eldebeiky M; Amer H; Akeel S; Morsy A; Amin A; Shafik A; Abaza S; Kaló Z
J Pharm Policy Pract; 2022 Mar; 15(1):10. PubMed ID: 35232487
[TBL] [Abstract][Full Text] [Related]
42. Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study.
Abdallah K; Claes K; Huys I; Follon L; Calis C; Simoens S
Orphanet J Rare Dis; 2022 Dec; 17(1):429. PubMed ID: 36494733
[TBL] [Abstract][Full Text] [Related]
43. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets.
Brixner D; Maniadakis N; Kaló Z; Hu S; Shen J; Wijaya K
Value Health Reg Issues; 2017 Sep; 13():1-6. PubMed ID: 29073981
[TBL] [Abstract][Full Text] [Related]
44. Patient involvement in reflective multicriteria decision analysis to assist decision making in oncology.
Badia X; Aguarón A; Fernández A; Gimón A; Nafria B; Gaspar B; Guarga L; Gálvez M; Fuentes M; Paco N; Saldaña R
Int J Technol Assess Health Care; 2019 Jan; 35(1):56-63. PubMed ID: 30730288
[TBL] [Abstract][Full Text] [Related]
45. The application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: a literature review.
Su P; Zhi K; Xu H; Xiao J; Liu J; Wang Z; Liu Q; Yu Y; Dang H
Front Pharmacol; 2024; 15():1245825. PubMed ID: 38720775
[No Abstract] [Full Text] [Related]
46. Consensus-Based Recommendations for the Implementation of Health Technology Assessment in the United Arab Emirates.
Alnaqbi KA; Elshamy AM; Gebran N; Fahmy S; Aldallal S; Korra N; Fasseeh AN; Kaló Z
Value Health Reg Issues; 2024 Jun; 43():101012. PubMed ID: 38861786
[TBL] [Abstract][Full Text] [Related]
47. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
[TBL] [Abstract][Full Text] [Related]
48. Ranking Decision-Making Criteria for Early Adoption of Innovative Surgical Technologies.
Shoman H; Almeida ND; Tanzer M
JAMA Netw Open; 2023 Nov; 6(11):e2343703. PubMed ID: 37971741
[TBL] [Abstract][Full Text] [Related]
49. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
Diaby V; Lachaine J
Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
[TBL] [Abstract][Full Text] [Related]
50. Critical assessment of belgian reimbursement dossiers of orphan drugs.
Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
[TBL] [Abstract][Full Text] [Related]
51. A multi-criteria decision approach for ranking unmet needs in healthcare.
Cleemput I; Devriese S; Kohn L; Westhovens R
Health Policy; 2018 Aug; 122(8):878-884. PubMed ID: 29983193
[TBL] [Abstract][Full Text] [Related]
52. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
53. Reimbursement of orphan drugs in Belgium: what (else) matters?
Picavet E; Cassiman D; Simoens S
Orphanet J Rare Dis; 2014 Sep; 9():139. PubMed ID: 25208770
[TBL] [Abstract][Full Text] [Related]
54. Value contribution of cenobamate for the treatment of Focal-Onset Seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through reflective Multi-Criteria Decision Analysis (MCDA).
Falip M; López González FJ; Martín-Herranz I; Merino-Bohórquez V; Montoya J; Rey Gómez-Serranillos I; Rodriguez Uranga JJ; Ruiz E; Sancho-López A; Trillo Mata JL; Antoni Vallès J; Álvarez-Barón E; Sabaniego J; Subías-Labazuy S; Gil A
Epilepsy Behav; 2023 Aug; 145():109350. PubMed ID: 37480633
[TBL] [Abstract][Full Text] [Related]
55. Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.
Angelis A; Linch M; Montibeller G; Molina-Lopez T; Zawada A; Orzel K; Arickx F; Espin J; Kanavos P
Soc Sci Med; 2020 Feb; 246():112595. PubMed ID: 31874372
[TBL] [Abstract][Full Text] [Related]
56. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.
Paulden M; Stafinski T; Menon D; McCabe C
Pharmacoeconomics; 2015 Mar; 33(3):255-69. PubMed ID: 25412735
[TBL] [Abstract][Full Text] [Related]
57. Insurance companies' perspectives on the orphan drug pipeline.
Handfield R; Feldstein J
Am Health Drug Benefits; 2013 Nov; 6(9):589-98. PubMed ID: 24991385
[TBL] [Abstract][Full Text] [Related]
58. Overview of Procurement and Reimbursement of Pharmaceuticals in Saudi Arabia, United Arab Emirates, Qatar, and Egypt: Challenges and Opportunities.
Hamad A; Alsaqa'aby M; Alruthia Y; Aldallal S; Elsisi GH
Glob J Qual Saf Healthc; 2023 Nov; 6(4):127-136. PubMed ID: 38404458
[TBL] [Abstract][Full Text] [Related]
59. Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.
Miot J; Wagner M; Khoury H; Rindress D; Goetghebeur MM
Cost Eff Resour Alloc; 2012 Feb; 10(1):2. PubMed ID: 22376143
[TBL] [Abstract][Full Text] [Related]
60. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
